Director at U S Physical Therapy (NYSE: USPH) receives stock grant
U S Physical Therapy director Anne Motsenbocker was granted 2,306 restricted shares of common stock at $61.61 per share as equity compensation, increasing her direct holdings to 9,812 shares. The restricted shares will vest in three tranches between August 2026 and March 2027, provided she remains a director. This insider transaction was reported via a Form 4 filing and is part of the company's 2003 Stock Incentive Plan.
[Form 4] U S PHYSICAL THERAPY INC /NV Insider Trading Activity
This article details an insider trading activity for U.S. Physical Therapy Inc. (USPH), focusing on a Form 4 filing by director Peter Francis Minan. Minan received a grant of 2,306 shares of Common Stock as restricted stock, valued at $61.61 per share, increasing his direct holdings to 2,431 shares. The restricted shares will vest in three tranches between August 2026 and March 2027, contingent on his continued service as a director.
US Physical Therapy (USPH) awards 2,306 restricted shares to director Harris
US Physical Therapy (USPH) director Bernard A. Harris Jr. has been granted 2,306 restricted shares at a reference price of $61.61 per share. This award, detailed in a Form 4 filing, increases his direct holdings to 20,914 shares. The shares will vest in three tranches on August 20, 2026, November 20, 2026, and March 6, 2027, provided he remains a director.
U.S. Physical Therapy (USPH) director granted 2,306 restricted shares as equity pay
U.S. Physical Therapy (USPH) director Kathleen A. Gilmartin was granted 2,306 restricted shares of Common Stock, valued at $61.61 per share, as equity compensation. This award increases her direct holdings to 27,092 shares, with vesting occurring in stages through March 6, 2027, contingent on her continued board service. The grant was made under the Company's Amended and Restated 2003 Stock Incentive Plan and is detailed in a recent Form 4 SEC filing.
US Physical Therapy Shareholders Back Board, Pay, Auditor
U.S. Physical Therapy (USPH) shareholders re-elected seven directors, approved executive compensation, and ratified Grant Thornton LLP as the independent auditor during their Annual Meeting on May 19, 2026. This indicates continued support for the company's leadership, compensation practices, and financial oversight. TipRanks' AI Analyst, Spark, assesses USPH as Neutral due to mixed fundamentals, technical drags, and mixed valuation, despite reaffirmed EBITDA guidance and strong visit trends.
USPH (USPH) director Peter Minan discloses initial 125-share stake
Peter Francis Minan, a director at U S Physical Therapy, Inc. (USPH), has filed an initial Form 3, reporting a direct beneficial ownership of 125 shares of the company's Common Stock. This filing establishes his initial stake in the company but does not indicate any recent purchases or sales. The Form 3 clarifies that Minan holds 125 shares directly, with no derivative securities reported.
U.S. Physical Therapy shareholders approve all proposals at annual meeting
U.S. Physical Therapy, Inc. (NYSE:USPH) announced that its shareholders approved all three proposals at its annual meeting held on May 19, 2026. This includes the election of seven directors, the advisory vote on executive compensation, and the ratification of Grant Thornton LLP as the independent accounting firm. Despite the positive shareholder vote, the company's stock is trading near its 52-week low, and it recently reported a significant earnings and revenue miss for Q1 2026.
[8-K] U S PHYSICAL THERAPY INC /NV Reports Material Event
U.S. Physical Therapy, Inc. reported the results of its Annual Meeting of Shareholders held on May 19, 2026. Shareholders elected seven directors, approved named executive officer compensation on an advisory basis, and ratified the appointment of Grant Thornton LLP as independent registered public accounting firm for the year ending December 31, 2026. The SEC filing details the votes for each proposal, including specific director votes and the advisory say-on-pay results.
Why It Might Not Make Sense To Buy U.S. Physical Therapy, Inc. (NYSE:USPH) For Its Upcoming Dividend
U.S. Physical Therapy, Inc. (NYSE:USPH) is preparing for an ex-dividend date; however, investors should consider that the company paid out 358% of its profits as dividends last year, which is unsustainable, despite its cash flow comfortably covering the dividend at 41%. The company has also experienced a 27% annual decline in earnings over the past five years, raising concerns about the long-term sustainability and growth potential of its dividend.
U.S. Physical Therapy Q1 2026 Earnings: Margins Squeezed by Winter Storms - News and Statistics
U.S. Physical Therapy reported first-quarter 2026 results that missed analyst expectations, primarily due to severe winter weather leading to lost patient visits and higher fixed costs, along with upfront investments. Revenue nearly matched estimates, reaching $198.3 million, but adjusted EPS and EBITDA fell short. Management confirmed that full-year EBITDA guidance accounts for the Q1 impacts and ongoing initiatives, including hospital partnerships and acquisitions.
U.S. Physical Therapy Presented at the BofA Securities 2026 Healthcare Conference
U.S. Physical Therapy, Inc. announced that its Chairman and CEO, Chris Reading, presented at the BofA Securities 2026 Healthcare Conference on May 13, 2026. Reading discussed the healthcare operating environment, the Company's initiatives, and growth opportunities. U.S. Physical Therapy operates 784 outpatient physical therapy clinics and provides industrial injury prevention services across 44 states.
US Physical Therapy Price Target Cut to $90.00/Share From $103.00 by Barrington Research
Barrington Research has adjusted its price target for US Physical Therapy (USPh) shares, lowering it to $90.00 from $103.00. Despite the reduction in the price target, the firm maintained its "Outperform" rating on the company's stock. This indicates that Barrington still sees potential for the stock to perform well, even with a revised valuation.
U.S. Physical Therapy, Inc. 2026 Q1 - Results - Earnings Call Presentation (NYSE:USPH) 2026-05-12
U.S. Physical Therapy, Inc. (NYSE:USPH) released its Q1 2026 earnings, reporting an EPS of $0.46, which missed expectations by $0.06. The company's revenue reached $198.29 million, a 7.89% year-over-year increase, but also fell short of estimates by $2.66 million. This article presents the slide deck published in conjunction with their earnings call.
U.S. Physical Therapy (USPH) Stock Is Up, What You Need To Know
U.S. Physical Therapy (USPH) shares saw a 4.4% increase after the company reported strong first-quarter 2026 results, including a 7.9% rise in revenue and confirmed its full-year financial outlook. This positive performance was driven by increased patient visits and strategic expansions. Despite this recent jump, the stock is still down 21.4% year-to-date and 33.4% below its 52-week high, with a prior report indicating a drop in profitability despite revenue beating expectations.
A Look At U.S. Physical Therapy’s Valuation After Mixed Q1 2026 Earnings And Share Price Weakness
U.S. Physical Therapy reported mixed Q1 2026 results, with revenue up but net income down, leading to a significant share price decline. Despite a high Price-to-Earnings ratio of 117.2x suggesting overvaluation compared to peers and industry averages, a Discounted Cash Flow model indicates the stock may be undervalued at $155.63 per share against its current price of $59. The article advises investors to weigh these conflicting valuations and further investigate the risks and rewards.
U.S. Physical Therapy Posts Strong Q1 2026 Revenue Growth
U.S. Physical Therapy (USPH) reported strong first-quarter 2026 results, with a 7.9% year-over-year increase in total revenue and robust growth in both its physical therapy and injury prevention segments. The company expanded its network and reaffirmed its 2026 guidance, citing ongoing technology initiatives and hospital partnerships despite challenges like weather disruptions and Medicaid rate pressure. Spark, TipRanks’ AI Analyst, rates USPH as Neutral due to solid revenue growth and cash flow balanced against profitability compression and weak technical signals.
U.S. Physical Therapy posts Q1 revenue of $198M, reaffirms 2026 adjusted EBITDA guidance
U.S. Physical Therapy (USPH) reported Q1 revenue of $198 million, marking a 7.9% year-over-year increase, and reaffirmed its full-year 2026 adjusted EBITDA guidance of $102M–$106M. Key highlights include a 6.9% rise in total patient visits, improved physical therapy revenue with increased net patient revenue per visit, and higher IIP revenue and margin. The company also completed two acquisitions and upsized its credit facility during the quarter.
US Physical Therapy (NYSE: USPH) posts Q1 2026 growth and keeps EBITDA outlook
U.S. Physical Therapy (USPH) reported Q1 2026 results showing revenue growth across its physical therapy and industrial injury prevention segments, maintaining its full-year 2026 adjusted EBITDA guidance of $102 million to $106 million. The company experienced robust patient volume despite weather impacts and completed two acquisitions, while also securing a new $450 million credit facility to support future growth and investments. Although net income declined due to non-cash items, management expressed confidence in their strategic initiatives and ability to meet financial goals for the year.
A Look At U.S. Physical Therapy’s Valuation After Mixed Q1 2026 Earnings And Share Price Weakness
U.S. Physical Therapy (USPH) reported mixed Q1 2026 results with revenue growth but decreased net income, leading to a significant share price decline. While the P/E ratio of 117.2x suggests the stock is overvalued compared to peers and its own historical profit trends, a discounted cash flow (DCF) model estimates a fair value much higher than its current share price, indicating conflicting valuation narratives for investors. The article encourages investors to conduct further research into the risks and rewards.
U.S. Physical Therapy (NYSE: USPH) grows Q1 2026 revenue but EPS turns negative
U.S. Physical Therapy (USPH) reported an increase in Q1 2026 net revenue to $198.3 million, up from $183.8 million in Q1 2025. However, due to higher operating costs, increased interest expense, and significant non-cash revaluation charges, operating income declined and the company experienced a net loss per share of $(0.12) compared to earnings of $0.80 per share in the prior year. The company continues its acquisition strategy, investing approximately $21.7 million in new businesses during the quarter.
Copeland Capital holds 836,831 shares in U S PHYSICAL THERAPY (USPH)
Copeland Capital Management has reported a beneficial ownership of 836,831 shares of U.S. PHYSICAL THERAPY INC (USPH) common stock, which represents a 5.5% stake as of March 31, 2026. The Schedule 13G filing indicates a passive investment intent, with the firm certifying that the stake is not held to influence control over the issuer. The filing details show substantial sole voting power for a portion of these shares, while the majority of shares have shared dispositive power.
US Physical Therapy Stock Has Fallen 25%, Time to Enter?
US Physical Therapy (USPH) stock has recently experienced a significant 24.7% drop in less than a month. Historically, such "sharp dips" (20% or more in under 30 days) have been followed by a median 12-month return of 4% and a median peak return of 35%. The company also passes basic financial quality checks, including revenue growth, profitability, cash flow, and balance sheet strength.
US Physical Therapy Stock Has Fallen 25%, Time to Enter?
US Physical Therapy (USPH) stock has recently experienced a 24.7% dip in less than a month. Historically, the stock has shown a median return of 4% in the 12-month period following such sharp dips, with a median peak return of 35%. The article suggests that USPH passes basic quality checks in terms of revenue growth, profitability, cash flow, and balance sheet strength, making the dip potentially a buying opportunity.
USPH Reports Q1 Revenue Below Expectations
US Physical Therapy Inc (USPH) reported Q1 revenue of $198.3 million, falling below analysts' expectations of $200.94 million. Despite the revenue miss, the company's leadership remains optimistic, focusing on initiatives to improve patient care and operational efficiency, including digitization and remote therapeutic monitoring. USPH's GF Score™ is 86/100, indicating strong fundamentals and growth, but its P/E ratio of 41.55x suggests the stock may be overvalued, and recent insider selling activity warrants caution for investors.
US Physical Therapy (USPH) Margin Slide To 1% Reinforces Bearish Earnings Narratives
U.S. Physical Therapy (USPH) reported a significant margin slide to 1% in Q1 2026, with a net income loss of US$1.8 million and basic EPS loss of US$0.12. This compression in profitability reinforces bearish narratives despite revenue growth, as indicated by a high P/E ratio and questions around the coverage of its dividend. The article discusses both bearish concerns and bullish arguments related to revenue growth and DCF fair value.
Earnings call transcript: USPH Q1 2026 reveals earnings miss, stock dips
U.S. Physical Therapy, Inc. (USPH) reported a significant earnings miss for Q1 2026, with a GAAP loss per share of $0.12 against an expected $0.54, and revenue of $198 million falling short of the $200.26 million forecast. The stock saw a 2% decline in aftermarket trading. Despite weather-related disruptions impacting patient visits and revenue, the company reaffirmed its full-year 2026 adjusted EBITDA guidance, citing strong growth in the Injury Prevention segment and ongoing initiatives to improve efficiency and expand cash-based programs. Management noted that the Q1 results were in line with their internal budget, and they anticipate a ramp-up in benefits from strategic investments and hospital partnerships throughout the year.
U.S. Physical Therapy (NYSE:USPH) - Stock Analysis
This Simply Wall St analysis provides an overview of U.S. Physical Therapy (NYSE:USPH), noting its current valuation, growth prospects, and financial health. The company is trading below its estimated fair value, with strong forecasted earnings growth, but faces risks like low profit margins and significant insider selling. Recent news includes a quarterly dividend announcement and a miss on analyst expectations for first-quarter 2026 earnings.
USPH Q1 2026 Earnings Call Transcript
U.S. Physical Therapy (USPH) reported Q1 2026 results, with total revenue up 7.9% to $198 million, driven by a 7.2% increase in physical therapy revenue and an 11.8% increase in Industrial Injury Prevention (IIP) revenue. Despite a GAAP loss per share due to revaluation of redeemable noncontrolling interest and weather-related visit losses, the company reaffirmed its full-year adjusted EBITDA guidance of $102 million to $106 million, confident in ongoing initiatives like hospital affiliations, cash-based programs, and technology investments. Management highlighted new credit facility, strategic acquisitions, and improved clinician retention as key strengths for future growth.
U.S. Physical Therapy Down Over 16%, On Track for Lowest Close Since April 2020 -- Data Talk
U.S. Physical Therapy (USPH) saw its stock decline over 16%, putting it on track for its lowest closing price since April 2020. This significant drop is noted in a "Data Talk" update, highlighting the stock's current performance trend.
US Physical Therapy stock hits 52-week low at $65.89
US Physical Therapy Inc. (USPH) stock dropped to a 52-week low of $65.87, slightly below its previous low. Despite the recent decline, the company shows strong fundamentals with 16.39% revenue growth over the last year and a market cap of $1.11 billion. InvestingPro analysis suggests the stock is undervalued, highlighting its consistent dividend increases for five years and a 2.5% dividend yield, with net income projected to grow.
US Physical Therapy 1Q Loss/Shr 12c >USPH
This article reports that US Physical Therapy (USPH) experienced a loss per share of 12 cents in the first quarter. This financial update indicates the company's performance for the period.
U.S. Physical Therapy: Q1 Earnings Snapshot
U.S. Physical Therapy Inc. (USPH) reported first-quarter net income of $5 million, with an adjusted EPS of 46 cents, falling short of analyst expectations of 55 cents per share. The company's revenue of $198.3 million also missed Street forecasts of $203.5 million. These figures were generated by Automated Insights using data from Zacks Investment Research.
U.S. Physical Therapy’s (NYSE:USPH) Q1 CY2026 Earnings Results: Revenue In Line With Expectations
U.S. Physical Therapy (NYSE: USPH) reported Q1 CY2026 earnings with revenue of $198.3 million, meeting analyst expectations, but a GAAP loss of $0.12 per share, significantly missing estimates. The company's adjusted EBITDA also fell below projections, and its operating margin decreased year-over-year. Despite these challenges, the company highlighted new initiatives aimed at improving efficiency and care, expecting them to bear fruit in the latter half of the year.
Here's What Key Metrics Tell Us About U.S. Physical Therapy (USPH) Q1 Earnings
U.S. Physical Therapy (USPH) reported its Q1 2026 earnings, with revenue up 7.9% year-over-year but missing the Zacks Consensus Estimate, and EPS also falling short of expectations. Key metrics like net rate per patient visit and patient visits were slightly below analyst averages. The company's stock has underperformed the S&P 500 recently and currently holds a Zacks Rank #5 (Strong Sell).
U.S. Physical Therapy Reports Record First Quarter Revenue, Reaffirms Full Year Guidance
U.S. Physical Therapy, Inc. reported record first-quarter revenue of $198.3 million for Q1 2026, marking a 7.9% increase from the prior year, and reaffirmed its full-year 2026 adjusted EBITDA guidance of $102.0 million to $106.0 million. Despite a decrease in net income attributable to USPH shareholders due to a loss on the change in fair value of contingent earn-out consideration and the dilutive effect of increased redeemable noncontrolling interests, the company saw growth in both physical therapy and industrial injury prevention segments. The company also announced the closing of an expanded $450 million credit facility, providing significant capacity for future growth and strategic affiliations.
Earnings Flash (USPH) U.S. Physical Therapy, Inc. Reports Q1 Revenue $198.3M, vs. FactSet Est of $200.9M
U.S. Physical Therapy, Inc. (USPH) reported its first-quarter revenue of $198.3 million, falling short of the FactSet estimate of $200.9 million. The company also posted Q1 adjusted EPS of $0.46 per share, which was below the FactSet estimate of $0.52. These figures highlight a miss on both revenue and adjusted earnings per share expectations for the quarter.
Record Q1 revenue as U.S. Physical Therapy (NYSE: USPH) reaffirms 2026 outlook
U.S. Physical Therapy (USPH) reported record Q1 2026 net revenue of $198.3 million, a 7.9% increase year-over-year, reaffirming its full-year 2026 adjusted EBITDA guidance of $102.0 million to $106.0 million. While adjusted EBITDA rose to $20.2 million, net income attributable to shareholders decreased to $5.0 million, resulting in a loss per share of $0.12 due to non-operating adjustments. The company also declared a quarterly dividend of $0.46 per share and outlined positive contributions from strategic hospital alliances.
US Physical Therapy faces earnings test after estimate cuts By Investing.com
U.S. Physical Therapy (USPH) is set to report its first-quarter earnings with analysts expecting a sequential decline in earnings despite an aggressive expansion strategy. The company's new hospital partnership strategy and same-store sales trends will be key areas of investor focus, especially given its premium valuation. USPH recently secured a $450 million credit facility to fund acquisitions, and the market will assess if this growth can offset near-term earnings pressure.
Price-Driven Insight from (USPH) for Rule-Based Strategy
This article provides a price-driven insight for U.s. Physical Therapy Inc. (NASDAQ: USPH) based on AI-generated signals. It highlights weak near and mid-term sentiment, elevated downside risk, and presents institutional trading strategies tailored to different risk profiles. The analysis includes position trading, momentum breakout, and risk hedging strategies, along with multi-timeframe signal analysis.
U.S. Physical Therapy, Inc. (NYSE:USPH) Receives Average Rating of "Moderate Buy" from Brokerages
U.S. Physical Therapy, Inc. (NYSE:USPH) has received an average "Moderate Buy" rating from six brokerages. Analysts have set an average one-year price target of $101.67, significantly higher than the current share price of $71.71. The company recently reported in-line EPS of $0.67 and revenue that beat expectations at $202.73M, and also announced an increased quarterly dividend of $0.46 per share.
U.S. Physical Therapy (NYSE:USPH) Cut to Strong Sell at Zacks Research
Zacks Research has downgraded U.S. Physical Therapy (NYSE:USPH) to a "strong sell" from a "hold," despite the average analyst rating remaining a "Moderate Buy" with a target price of $101.67. The company recently beat revenue estimates with $202.73 million and met EPS expectations at $0.67, with a 12.3% year-over-year revenue increase. However, the stock trades at a high P/E of 50.2, and there has been mixed insider and institutional investor activity, with some insiders selling shares while large institutions increased their stakes.
Vanguard reports 5.14% stake in US Physical Therapy (NASDAQ: USPH)
Vanguard Capital Management has disclosed a 5.14% stake in US Physical Therapy Inc. (NASDAQ: USPH), holding 777,590 shares of common stock. This is reported in a Schedule 13G filing, indicating a passive investment, with Vanguard having sole dispositive power over all shares and sole voting power over 113,528 shares. The filing's impact is deemed neutral as it does not signal active intent or changes in holdings.
U.S. Physical Therapy (USPH) Expected to Announce Quarterly Earnings on Wednesday
U.S. Physical Therapy (USPH) is slated to release its Q1 2026 earnings after market close on Wednesday, May 6th, with analysts projecting $0.55 EPS and $200.94 million in revenue. The company recently reported $0.67 EPS and $202.73 million revenue for the prior quarter and increased its quarterly dividend to $0.46. Analyst ratings for USPH average a "Moderate Buy" with a consensus price target of $101.67.
US Physical Therapy (USPH) interim CFO details restricted stock vesting
U.S. Physical Therapy, Inc.'s interim CFO, Jason Travis, filed an initial ownership report revealing beneficial ownership of 3,933 shares of common stock. Of these, 3,767 shares are restricted stock granted under the company’s Amended and Restated 2003 Stock Incentive Plan and will vest in multiple tranches between May 20, 2026, and March 6, 2030, contingent on his continued service. The report provides detailed dates and share amounts for each vesting event, including a significant 1,250-share tranche vesting on May 15, 2027.
(USPH) Price Dynamics and Execution-Aware Positioning
This article provides an AI-driven analysis of U.s. Physical Therapy Inc. (NASDAQ: USPH), focusing on price dynamics and execution-aware positioning. It identifies a weak near-term sentiment that could lead to bearish positioning and highlights an exceptional 38.8:1 risk-reward setup targeting an 11.2% gain. The analysis also outlines specific institutional trading strategies for various risk profiles, including position trading, momentum breakout, and risk hedging.
Boston Trust Walden Corp Trims Stock Holdings in U.S. Physical Therapy, Inc. $USPH
Boston Trust Walden Corp has reduced its stake in U.S. Physical Therapy by 7.7%, selling 37,754 shares and now owning 452,314 shares valued at approximately $35.3 million. This comes as U.S. Physical Therapy reported solid Q4 results, exceeding revenue expectations and raising its quarterly dividend to $0.46 per share. Despite some insider selling, analysts maintain a "Moderate Buy" rating with an average price target of $101.67 for the stock.
How many employees work at US Physical Therapy?
U.S. Physical Therapy, Inc. currently employs 4,478 individuals, showing a year-over-year growth rate of 0.5% as of December 2025. The company operates numerous outpatient physical and occupational therapy clinics across over 41 states, often through partnerships with local owners. Revelio Labs data indicates consistent employee growth and significant increases in active job postings over recent years.
How USPH’s Expanded $450 Million Credit Facility Could Reshape U.S. Physical Therapy’s Investment Playbook
U.S. Physical Therapy, Inc. (USPH) recently secured an expanded $450 million credit facility, enhancing its financial flexibility for acquisitions, growth, and refinancing existing debt. While this strengthens the company's ability to pursue acquisition and partnership-driven growth, the underlying investment narrative still hinges on adeptly managing reimbursement pressures and rising labor costs. Investors should monitor how the increased credit capacity translates into shareholder value amid these challenges.
U.S. Physical Therapy: $450 Million Credit Facility Strengthens Growth And Capital Flexibility
U.S. Physical Therapy has secured a new $450 million, five-year credit facility, upsized from an initial $400 million, to support its continued growth and strategic initiatives. This facility enhances the company's financial flexibility, providing increased borrowing capacity and improved pricing. U.S. Physical Therapy plans to use these funds to expand its clinic portfolio and industrial injury prevention services, while also returning capital to shareholders.
How USPH’s Expanded $450 Million Credit Facility Could Reshape U.S. Physical Therapy’s Investment Playbook
U.S. Physical Therapy (USPH) recently secured an expanded $450 million senior credit facility, including a $275 million revolving credit line, which aims to enhance financial flexibility for acquisitions, growth, and debt refinancing. This move, coupled with a major alliance with NYU Langone Health, underscores a growth strategy heavily reliant on partnerships and acquisitions. While the increased credit facility offers strategic advantages, investors are still advised to monitor potential impacts from reimbursement pressures and regulatory changes on the company's margins and projected revenue growth.
